Audit: QRS - Eleutherosides for Health & Longevity

Audit conducted on 16/08/2026 03:09 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Verified item by item against the ER: protocol values (lines 379-393), time-to-effect (line 440), benefit and risk tiers (lines 145-301), gates (lines 323-353), biomarker rows (lines 474-482), cadence (line 470).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Tier wording, “Conflicted” items and speculative framing are carried at the ER’s own strength.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain absolute framing (e.g. “Uncontrolled hypertension (above 160/100 mmHg)”); no gate is softened to a caution and no speculative item is promoted.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid” list, interactions from the ER interaction bullets, risks from Potential Risks & Side Effects; no cross-category relabelling.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, author names, NCT identifiers or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attribution is present that the ER does not carry.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, evidence-weighted register matching the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven while remaining accessible and actionable.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents findings and ranges rather than instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive clinical directives in the variable content.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Values and cadences are stated, not recommended.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address in any variable region.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Terminology is no more technical than the ER’s, and the At-A-Glance uses plain equivalents (“leg swelling”, “disturbed sleep”).
2.8	Information is presented in a concise and very compact manner	🟢	All items are bare noun phrases; no elaboration carried over.
2.9	It DOES NOT address the reader directly	🟢	No second-person address in any variable region.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Monitoring panel, standardization target and cycling-relevant timing address a proactive, risk-aware audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Presents a 9-marker panel, timed dosing and identity verification without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content depth exceeds general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Product-identity hazard and stress-axis caveat are foregrounded, matching the ER’s weighting for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The term “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology throughout (“adverse events”, “neurological deficit”, “lower-limb swelling”).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and table column headers are present verbatim (lines 446, 490, 538, 567, 581, 604, 634, 638-640, 768).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template variable spans are present: page_title, header_, at_a_glance, action_1-3_, time_1-3*, benefits, stop_items, caution_items, risks_, marker_1-9_*, monitoring_cadence, qualitative_item_1-7.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-audited spans (website=”evidence_review”, website=”audit”, website=”full_review”) and all CSS/structure are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No section of the source ER is empty, so no empty-state phrasing applies.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels reuse the ER’s bold labels verbatim: “Standard dose range”, “Standardization target”, “Best time of day” (ER lines 379, 381, 389).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names and qualitative items are carried verbatim from the ER tables and list.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No 🟩/🟥/🟨 or any other emoji indicator appears in the file.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to bare items with explanations, magnitudes and citations stripped; no content is spilled into an added page or block.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment opens at line 2, immediately after <!doctype html>, before any other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3 and closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element on the sheet surfaces it.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon, which requires YAML quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: eleutherosides_2026-0825-0026_Opus_ER.md (line 4) matches the source ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 (line 5) matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0816-0247 (line 6) is in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (line 7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (line 8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: eleutherosides_2026-0825-0026_Opus_QRS.html (line 9) matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	No stray whitespace or unnecessary quoting in any value.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &)	🟢	<title>Eleutherosides for Health &amp; Longevity - Quick Reference Sheet</title> (line 22), with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &)	🟢	[header_topic] is “Eleutherosides for Health & Longevity” (line 417), matching canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	“08/16/2026” (line 421) is 2026-0816-0247 in MM/DD/YYYY form.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425) matches qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The subline carries only the template’s fixed date/model/AI4L elements; no badge, AKA line, version stamp or audit date.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (lines 517-523): marker-compound identity, mixed modern results, modest harms, product-identity hazard.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words, under the 60-word limit.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion passage (ER lines 517, 519, 521).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; plain-language terms used throughout (“leg swelling”, “disturbed sleep”, “product identity”).
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, sample sizes or p-values; the single date refers to when the Soviet archive became readable in English, matching ER line 517.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, risk ratios or statistical results.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Derived from the ER “Populations who should avoid Eleutherosides” list (ER lines 345-353).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER populations are represented as [stop_items] (lines 570-576).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is a discrete <li> inside the [stop_items] span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER trailing em-dash rationale is stripped (e.g. “— no controlled safety data…” removed from Pregnancy and breastfeeding).
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Threshold and time-window parentheticals retained: “(above 160/100 mmHg)” and “(<90 days)”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, matching the ER’s seven avoid-populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Contraindications section is not left empty (7 items derived from the ER).

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Derived from the ER interaction bullets (ER lines 323-343).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eleven ER interaction bullets appear (lines 584-594); none duplicates a Contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is a discrete <li> inside the [caution_items] span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Caution/Monitor verdicts, consequences and mitigation clauses are all stripped; only the agent or class remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists are preserved and trimmed to fit, e.g. “(sertraline, paroxetine, duloxetine)”, “(metformin, sulfonylureas, insulin)”, “(zolpidem, benzodiazepines)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated with all eleven ER interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Key Interactions section is not left empty (11 items derived from the ER).

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Derived from the ER Therapeutic Protocol section (ER lines 379-403).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose range, standardization target and dosing time are the three load-bearing implementation aspects of the ER protocol.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section supplies three distinct actionable aspects; no unused sets.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields carry ER-derived content (lines 450-486).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Lower-limb swelling, endurance, and fatigue/immune measures are the three time-to-effect aspects the ER names (ER line 440).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered swelling (Medium-tier benefit) → endurance → fatigue/immune (both Low-tier).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; no unused sets.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields carry ER-derived content (lines 496-530).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (Practical Considerations, line 440), so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Derived from the ER Expected Benefits section (ER lines 141-227).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four tier spans are present (lines 540, 541, 547, 556).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are bare noun phrases; magnitudes, mechanisms and “⚠️ Conflicted” markers are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	[benefits_high] carries style="display: none" and no empty-state text, matching the ER’s empty High tier (ER line 147).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Derived from the ER Potential Risks & Side Effects section (ER lines 247-301).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four tier spans are present (lines 606, 611, 617, 623).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are bare noun phrases; magnitudes, case counts and mechanisms are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk sub-sections (high, medium, low, speculative) carry items in the ER, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success table (ER lines 472-483).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine quantifiable biomarkers with functional ranges are listed with matching targets; the tenth ER row, “Subjective sleep latency”, has no established target and is carried in Qualitative Assessment.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with the ER’s cadence, including the tighter medicated-user schedule (ER line 470).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER’s qualitative marker list (ER lines 487-493).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers are listed as [qualitative_item_1] through [qualitative_item_7].

Issues 16/08/2026 03:09

Pass rate 100.00%. No issues found.

Issues 16/08/2026 03:02

1. 1.1 — Qualitative marker broadened: Qualitative Assessment item 6 (line 795) reads “Frequency and duration of respiratory infections over a season”, dropping “upper” from the ER’s “upper respiratory infections” (ER line 492), which broadens the marker beyond the ER’s statement.

Fixes 16/08/2026 03:02

1. 1.1 — Qualitative marker broadened: Restored “upper” in Qualitative Assessment item 6, changing “Frequency and duration of respiratory infections over a season” to “Frequency and duration of upper respiratory infections over a season” to match the ER wording.

Issues 16/08/2026 02:51

1. 4.5 — Content exceeds one A4 page: The combined header, At-A-Glance, protocol panel, benefits card and decision gates already fill the print budget, leaving the risks card, the nine-row monitoring table and the seven-item qualitative card to overflow onto a second page.
2. 7.2 — At-A-Glance over word limit: The [at_a_glance] text at lines 434-438 runs to 61 words against the 60-word maximum.

Fixes 16/08/2026 02:51

1. 7.2 — At-A-Glance word count: Tightened the [at_a_glance] text (“carrying a reputation” → “with a reputation”, “fatigue relief shows up only in milder cases” → “fatigue relief only in milder cases”), bringing it from 61 to 59 words.
2. 4.5 — Protocol and time-to-effect sub-lines condensed: Shortened all six sub-lines, e.g. action_1_sub dropped “the range used across the modern controlled trials” and time_3_sub dropped “a four-week minimum trial is reasonable”.
3. 4.5 — Benefits and risks items tightened: Rewrote the medium and low benefit runs and the medium and low risk runs in shorter form (e.g. “Reduction of lower-limb swelling” → “Reduced lower-limb swelling”, “adverse events in combination with antidepressant medication” → “adverse events with antidepressants”).
4. 4.5 — Decision-gate items trimmed: Shortened contraindication and interaction wording and pruned redundant example drugs while keeping every qualifier (e.g. “Uncontrolled hypertension (resting blood pressure above 160/100 mmHg)” → “(above 160/100 mmHg)”; anticoagulant list reduced to warfarin, apixaban, aspirin).
5. 4.5 — Monitoring “Why” cells and cadence shortened: Trimmed four “Why” cells and rewrote the cadence text (“Baseline before starting, drawn fasting between 07:00 and 09:00” → “Baseline fasting 07:00–09:00”), removing roughly a line from the table and the cadence paragraph.
6. 4.5 — Qualitative items shortened: Condensed two items (“Irritability and restlessness, particularly in the first two weeks” → “Irritability and restlessness in the first two weeks”; “upper respiratory infections” → “respiratory infections”).